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Abstract
Background: We investigated the impact of antimicrobials in cervicovaginal lavage (CVL) from HIV(+) and HIV(2) women on
target cell infection with HIV. Since female reproductive tract (FRT) secretions contain a spectrum of antimicrobials, we
hypothesized that CVL from healthy HIV(+) and (2) women inhibit HIV infection.
Methodology/Principal Findings: CVL from 32 HIV(+) healthy women with high CD4 counts and 15 healthy HIV(2) women
were collected by gently washing the cervicovaginal area with 10 ml of sterile normal saline. Following centrifugation, anti-
HIV activity in CVL was determined by incubating CVL with HIV prior to addition to TZM-bl cells. Antimicrobials and anti-
gp160 HIV IgG antibodies were measured by ELISA. When CXCR4 and CCR5 tropic HIV-1 were incubated with CVL from
HIV(+) women prior to addition to TZM-bl cells, anti-HIV activity in CVL ranged from none to 100% inhibition depending on
the viral strains used. CVL from HIV(2) controls showed comparable anti-HIV activity. Analysis of CH077.c (clone of an R5-
tropic, mucosally-transmitted founder virus) viral inhibition by CVL was comparable to laboratory strains. Measurement of
CVL for antimicrobials HBD2, trappin-2/elafin, SLPI and MIP3a indicated that each was present in CVL from HIV(+) and
HIV(2) women. HBD2 and MIP3a correlated with anti-HIV activity as did anti-gp160 HIV IgG antibodies in CVL from HIV(+)
women.
Conclusions/Significance: These findings indicate that CVL from healthy HIV(+) and HIV(2) women contain innate and
adaptive defense mechanisms that inhibit HIV infection. Our data suggest that innate endogenous antimicrobials and HIV-
specific IgG in the FRT can act in concert to contribute toward the anti-HIV activity of the CVL and may play a role in
inhibition of HIV transmission to women.
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Introduction
Heterosexual transmission of HIV is the predominant driver of
the growing HIV pandemic [1,2]. Yet, while considerable
attention has been directed to developing topical exogenous
microbicides that reduce transmission of HIV-1, relatively little is
known about endogenous microbicides produced within the
female reproductive tract (FRT). That endogenous microbicides
in the female reproductive tract secretions might limit or prevent
HIV transmission is suggested by the relatively low risk of HIV
transmission per heterosexual coitus, from 1:122 to 1:1000 [3,4].
We and others have shown that cells of the FRT produce and
secrete a spectrum of cytokines, chemokines, and antimicrobials
[5–8]. Several specifically inhibit HIV infection of target cells
[9,10]. Antimicrobials secreted by FRT cells include well-
characterized anti-HIV molecules, alpha/beta defensins, lactofer-
rin, and secretory leukocyte protease inhibitor (SLPI), as well as
factors such as trappin-2/elafin and MIP3a, which have recently
been shown to have anti-HIV activity [9–13]. Some of these
factors such as human beta defensins 2 (HBD2) act directly to
inhibit virus [10], while others including SDF1a, RANTES,
MIP1a, and MIP1b bind to co-receptors to prevent viral entry
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cationic polypeptides in CVL to anti-HSV and anti-HIV activity
[15,16]. Venkataraman et al. showed that when all cationic
polypeptides were depleted from the CVL, antimicrobial activity
was lost [16].
The isolation of HIV-1 in the FRT was first reported in 1986
[17]. Since then, numerous studies have reported the presence of
cell-free HIV-1 RNA, cell-associated HIV-1 RNA, proviral DNA,
and culturable virus from the cervix and vagina of pregnant and
non-pregnant infected women [18–20]. While it is clear that HIV-
1 is shed into the FRT, a detailed understanding of this
phenomenon and factors that affect the amount and infectivity
of virus in the FRT has not yet been elucidated. Reichelderfer et al.
reported that HIV-1 RNA levels in endocervical secretions were
highest in the week preceding menses [21]. Other studies have
shown no effect of the menstrual cycle on the amount or infectivity
of HIV-1 in the FRT [22]. In a recent study, the number of HIV-1
infected cells in endocervical secretions was reported to increase at
midcycle just after the periovulatory phase [23]. In other studies,
Cummins and colleagues showed that certain innate immune
factors in vaginal lavages were more closely associated with HIV-1
shedding in the genital mucosa than plasma viral load [24].
Whether virus is shed into the vagina from the upper FRT remains
to be determined. Whereas HIV-1 shedding in CVL secretions is
readily detectable, it remains unclear what percentage of the shed
virus is actually infectious [24,25].
In this study, we assessed the levels of multiple candidate
endogenous microbicides in cervicovaginal lavage (CVL) speci-
mens from HIV(+) and HIV(2) women, and characterized
whether these microbicides correlate with protection from HIV
infection. Of the four microbicides analyzed, we found that the
levels of two endogenous microbicides, HBD2 and MIP3a
correlated with activity against HIV. Analysis of CVL for HIV-
specific IgG of healthy HIV(+) women further indicated a positive
correlation with anti-HIV activity. These data indicate that CVL
from HIV(+) and HIV(2) women contain endogenously produced
antimicrobials and IgG (HIV+ samples) that correlate with
protection against HIV infection. Further, these findings suggest
that, as a consequence of antimicrobial activity in the lower FRT,
an environment exists for viral inactivation, which in part may
contribute to the low frequency of infectious virus found in FRT
secretions. The identification of endogenous microbicides that
inhibit HIV transmission should contribute both to our under-
standing of the pathogenesis of HIV-1, as well as facilitate the
development of novel microbicides capitalizing on existing host
immune mechanisms.
Methods
HIV(+) Participants
Specimen collection and patient information were provided as a
part of an observational study on HIV shedding in women. This
study was conducted according to the principles expressed in the
Declaration of Helsinki. The study was approved by the Miriam
Hospital Institutional Review Board (Brown University, Provi-
dence, RI). All patients (HIV(+) and HIV(2)) provided written
informed consent for the collection of samples and subsequent
analysis. Thirty two HIV(+), sexually abstinent women (48 hrs
prior to sampling) between the ages of 16 and 41 years were
recruited from The Immunology Center, Miriam Hospital
(Table 1). Enrollment criteria included a normal menstrual
history, not on hormonal contraceptives, CD4 T cell counts
above 350 cells/mm
3 (mean 713 (419–1517) cells/mm3), and no
exposure to antiretroviral (ARV) drugs. Participants agreed to
undergo colposcopic assessment, and were excluded for pregnan-
cy, breastfeeding, menopause, or inter-menstrual bleeding in the
previous three months. Additionally, women were excluded if they
had douched, used any vaginal products, or had sexual intercourse
during the 48 hrs prior to CVL collection. CVL was collected by
gently washing the cervicovaginal area with 10 ml of sterile
normal saline (pH,7.2). Following CVL collection, samples were
centrifuged at 10,0006g for 5 min after which supernatants and
cell pellets were stored at 280uC until used. Women were tested
for lower genital tract infections including but not limited to
bacterial vaginosis (BV), Trichomonas vaginalis, Neisseria gonorrhea and
Candida albicans. Race and ethnicity were self-defined by the
Table 1. HIV-1 Patient Demographics
a.
PATIENT
SUBJECT # RACE AGE PVL GTVL
CD4
count
1
* B3 3 ,400 ,400 419
2 B 23 23,000 ,400 459
3 B 35 3,300 ,400 510
4 B 41 12,000 ,400 517
5 B 38 20,000 9700 580
6 B 27 32,000 ,400 583
7 B 39 67,000 ,400 628
8 B 30 1,500 ,400 637
9
* B3 1 ,400 ,400 647
10 B 33 17,000 ,400 685
11
* B 27 6,629 ,400 772
12 B 24 10,000 ,400 863
13 H 31 840 ,400 426
14 H 27 9,300 ,400 510
15 H 36 ,400 ,400 620
16 H 28 ,400 ,400 799
17 H 32 54,000 ,400 813
18 H 31 ,400 ,400 899
19 H 27 3,600 460,000 901
20 H 16 5,200 4,700 1,517
21 W 28 3,500 ,400 496
22
* W 22 2,100 ,400 502
23 W 29 110,000 300,000 605
24 W 26 3,400 ,400 631
25
* W 18 8,000 ,400 637
26 W 32 ,400 ,400 651
27 W 30 ,400 ,400 677
28 W 22 7,600 ,400 822
29
* W 29 870 38,000 872
30
* W1 9 ,400 ,400 921
31 W 25 ,400 ,400 931
32 W 32 1,800 ,400 1,277
aCVL were recovered from HIV(+) women and stored in the HERS repository.
The lower level of detection of our viral load assay was 400 copies/ml. Women
self- identified by race as Black (B), Hispanic (H) or White (W). Also indicated is
the age of each individual, plasma viral RNA load (PVL), genital tract viral RNA
load (GTVL) and CD4 counts (cells/mm
3).
*Denotes women with STDs; #1, 22, 25 had BV; #11 had Trichomonas; #9, 30
had BV/Trich; #29 had BV/fungus.
doi:10.1371/journal.pone.0011366.t001
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and genital tract viral load (GTVL) RNA as well as CD4 counts,
age and race are shown in Table 1.
HIV(2) Participants
CVL from participants in this study were obtained from the
Rhode Island site (Miriam Hospital, Brown University, Provi-
dence, RI) of the HIV Epidemiology Research (HER) study.
Women ranged in age from 24 to 34 yrs. Race was self-defined by
the women involved in the study. CVL was collected by gently
washing the cervicovaginal area with 10 ml of sterile normal saline
(pH,7.2). Following CVL collection, samples were immediately
frozen at 280uC. At the time of analysis, samples were thawed to
room temperature, centrifuged at 10,0006g for 5 min after which
supernatants were assayed for anti-HIV activity. In preliminary
studies (not shown), we compared CVL that were centrifuged after
collection and prior to freezing with those that were freeze-thawed
once prior to centrifugation and found no differences in anti-HIV
inhibitory activity.
HIV Viral Stocks
Laboratory-adapted viral strains HIV-1 IIIB (X4) and BaL (R5)
were obtained from Dr. P. Gupta (Univ. of Pittsburgh, PA). Virus
stocks were propagated in PHA-stimulated human PBMC and
stored frozen at 280uC. Virus stocks produced in PBMC of
molecularly cloned HIV-1 NL4.3 (X4; lab-adapted) and YU-2.c
(R5; directly cloned without culture) were used in this study. Virus
titers were determined on TZM-bl cells as described [26]. Also
used was a PBMC-derived virus stock of pCH077.c, a recently
generated Clade B infectious molecular clone ([27,28], Ochsen-
bauer et al., manuscript in preparation) matching the nucleotide
sequence determined to be the transmitted/founder virus
sequence of CHAVI subject 700010077.
Measurement of infectious HIV in CVL
Intrinsic anti-HIV activity in CVL was determined using TZM-
bl cells [26]. The TZM-bl indicator cell line is a HeLa cell
derivative that expresses high levels of CD4, CCR5 and CXCR4.
Cells contain HIV long terminal repeat (LTR)-driven b-galacto-
sidase and firefly luciferase reporter cassettes that are activated by
HIV infection and subsequent Tat protein expression [26]. TZM-
bl cells were routinely subcultured every 3 to 4 days by
trypsinization and maintained in TZM-bl media consisting of
phenol red-free DMEM (Invitrogen Life Technologies, Carlsbad,
CA) supplemented with 10% defined FBS (HyClone, Logan, UT,
USA), 2 mM L-glutamine (Invitrogen Life Technologies), and
50 mg/ml primocin (Invivogen, San Diego, CA, USA).
To measure the presence of infectious HIV-1 in CVL, TZM-bl
cells were seeded at 2610
4 cells per well in a 96-well microtiter plate
and allowed to adhere overnight at 37uC. Patient CVL samples
were diluted 1:4 in TZM-bl media prior to 100ml being added to
TZM-bl cells for 48h at 37uCi n5 %C O 2. Luciferase activity was
measured following manufacturer’s instructions. Briefly, following
aspiration of supernatants, a beta-glo luciferase substrate (Promega,
Madison, WI) solution (100ml) was added to cells. The light intensity
of each well was measured using a luminometer. Background
luminescence was determined by analyzing uninfected TZM-bl
cells. All infectivity assays were performed in quadruplicate. Media
diluted CVL had neutral pH values (pH 7.0–7.2).
Measurement of CVL anti-HIV-1 activity
TZM-bl cells were seeded at 2610
4 cells per well in a 96-well
microtiter plate and allowed to adhere overnight at 37uC. CVL
from individual patients were diluted 1:4 and incubated with virus
(MOI=1) for 1hr at 37uC in a final volume of 100ml. Following
incubation, media was aspirated from TZM-bl cells and the virus
plus CVL mixture (100ml) was added to the cells along with 100ml
of TZM-bl media. Luciferase activity was measured as described
above. Controls included incubation of TZM-bl with virus alone,
CVL alone and cells in media. Uninfected cells were used to
determine background luminescence and data was expressed in
relative light units (RLU). To calculate percent inhibition, the
RLU values of ‘‘virus only’’ wells were averaged and set to 100%.
Values of CVL treated virus were calculated as a percentage of the
‘‘virus only’’ and then subtracted from 100 to calculate %
inhibition. Viability of TZM-bl cells upon treatment with CVL
was quantified using the CellTiter 96H AQueous One Solution
Cell Proliferation Assay (Promega) according to manufacturer’s
instructions. Briefly, reagent was added directly to cell cultures and
incubated for 30 min at 37uC followed by reading the plate in a
plate reader at OD 490nm.
Measurement of antimicrobials in CVL
CVL supernatants were stored at 280uC until assayed for SLPI,
MIP3a and trappin-2/elafin with ELISA test kits or ELISA
Duoset kit from R&D Systems (Minneapolis, MN) according to
the manufacturer’s protocol. Standards for each ELISA were re-
suspended in phosphate buffered saline (PBS). Samples were also
diluted in 1xPBS. Cytokines were quantified based on standard
curves obtained using an ELISA reader (Dynex, Chantilly, VA).
HBD2 was assayed with an ELISA test kit from PeproTech (Rocky
Hill NJ) according to the manufacturer’s protocol.
Figure 1. Determination of the presence of infectious HIV-1 in
CVL from HIV(+) women. HIV(+) CVL from 32 patients were diluted 1:4
and added directly to TZM-bl cells. The assay was terminated 48h post-
infection and HIV-1 infection was quantified by measuring luciferase
reporter gene activity using a luminometer and expressed as relative
light units (RLU). Each data point in graph represents one individual
patient. In the Control (media only) column, each point represents
replicate wells. When comparing Controls with the CVL samples (TZM-bl
cells incubated with CVL), 3 out of 32 showed RLU levels at least 2-fold
abovebackground indicating that these 3 CVL containedinfectious HIV-1
which trans-activated the LTR-driven reporter gene.
doi:10.1371/journal.pone.0011366.g001
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levels in CVL
Specimens were tested by kinetic ELISA (kELISA) adapted
from an assay previously described for influenza [29]. The
kELISA measures substrate activation every 9 sec over the first
5 min of the enzymatic assay and plots the change in color per min
as mOD/min using a Thermomax microplate reader (Molecular
Devices, Sunnyvale, CA). Duplicate wells were coated with MN
strain gp160 (Protein Sciences, Meriden, CT). An uncoated well
was run with each sample to determine background, which was
subtracted from the result. A standard curve with a known positive
serum specimen was included in each assay as a measure of
sensitivity and reproducibility. Biotinylated anti-human IgG and
IgA conjugates were used with streptavidin-HRP and ABTS [29].
The presence of anti-HIV gp160 specific IgG and IgA antibodies
used 15mOD as a cut-off for detection.
Measurement of HIV-1 RNA in CVL and Plasma
Nucleic acid sequence-based amplification (BioMerieux, Dur-
ham, NC) was used to measure HIV-1 RNA as previously
described [30]. All results are expressed as copies per ml with a
lower limit of detection of 2.6 log10 (400) copies/ml for both
plasma and CVL.
Statistical analysis
Data were analyzed using GraphPad Prism (La Jolla, CA) and
STATA 9 (College Station, TX). Mean and standard error were
calculated for all data sets. Comparisons of anti-HIV activity
Table 2. Anti-HIV-1 activity and levels of antimicrobials in secretions from HIV(+) patients.
Patient X4 % Inhibition R5 (pg/ml)
Number IIIB NL4.3 YU2.c BaL CH077.c HBD2 Elafin MIP3a SLPI
1 66 82 12 30 52 50344 10499 1942 108000
25 1 8 6 257 26 34 44635 7441 246 103000
3 30 82 53 26 21 2089 4260 21 55340
4 85 84 30 46 37 34056 7820 481 105000
56 2 7 0 220 34 27 42438 9746 346 83710
6 260 246 286 258 243 10 2705 4 18040
7 90 87 1 81 55 48638 3226 669 112000
86 3 4 7 210 14 36 19925 2718 9 19510
9 65 68 65 60 89 52713 8316 1173 46800
10 231 0 1 4 220 32 36913 5664 405 76160
11 77 84 1 249 2134 60777 5503 4 14310
12 53 29 279 22 239 48809 7548 4 84320
13 11 220 245 14 26 23453 8248 19 87550
14 58 214 24 52 66 6539 1437 47 79190
15 77 66 29 56 53 7453 6800 136 32650
16 98 99 35 77 77 42876 1824 55 42400
17 19 23 219 28 57 1375 3182 113 22250
18 99 96 66 92 87 46164 32 15 35660
19 100 101 82 98 78 65573 8703 3409 107000
20 100 99 91 90 96 50670 4989 2469 100000
21 93 78 22 75 47 28611 3206 136 49780
22 79 27 66 15 41 22319 5328 62 38230
23 89 78 35 67 75 38803 7040 59 55380
24 25 219 23 0 25 10 226 36 12340
25 223 16 43 255 69 41898 6465 43 52480
26 261 29 25 265 231 26324 4316 146 121000
27 93 99 67 89 88 28985 3368 101 42770
28 95 93 67 63 50 49191 4307 40 27350
29 215 61 64 232 63 49555 3516 246 51640
30 95 100 92 86 96 15506 2 201 30330
31 38 62 49 31 72 37105 1894 12 8530
32 69 91 35 52 65 55500 4544 446 103000
MEDIAN 66 74 28 33 53 37954 4430 107 52060
INTERQUARTILE RANGE 28, 92 20, 89 26, 65 21, 71 30, 74 21122,
49000
2950,
7241
29, 376 31490,
93775
doi:10.1371/journal.pone.0011366.t002
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U tests, with a P value of less than 0.05 considered to be
significant. We analyzed the correlation between CVL microbicide
levels and the percent reduction in HIV infection of TZM-bl cells
using Spearman correlation coefficients with a P value threshold
for statistical significance of 0.05. The percent reduction in HIV
infection of TZM-bl cells for each isolate was divided into
quartiles, and a score assigned to each quartile. Then, to assess the
impact of a given CVL microbicide with inhibition of target cell
infection across viral strains, we assessed the correlation of levels of
each endogenous microbicide with summed quartile scores using
Spearman correlation coefficients as above.
Results
Infectious HIV-1 in Cervical Vaginal Lavage (CVL)
specimens from HIV(+) women
Table 1 shows the patient profiles of HIV(+) women indicating
age, race/ethnicity, CD4 count, plasma HIV viral load (PVL)
and genital tract HIV viral load (GTVL). Owing to the
conditions under which samples were collected, CVL were not
collected according to the menstrual cycle stage. Since current
methods of measuring GTVL do not distinguish between
infectious and non-infectious HIV [24,25], we used the TZM-
bl assay to measure HIV infectivity of CVL specimens and
correlated these data with GTVL, and PVL in our HIV(+)
patient population. We evaluated 32 CVL from HIV infected
women for infectious virus. CVL were obtained from HIV(+)
women, who had CD4+ cell counts greater than 350 cells/mm
3
and were not on anti-retroviral (ARV) therapy. Samples were
diluted 1:4 in media (final pH 7.0–7.2) and added to TZM-bl
cells to assess whether virus present in CVL was infectious. As
shown in Figure 1, CVL from 3 of 32 women contained virus
capable of infecting TZM-bl cells. On further analysis, we
observed that of the three women, 2 had bacterial vaginosis, a
known enhancement factor for HIV infection [31], and 1 had a
Trichomonas infection. We found no correlation between GTVL
(Table 1), PVL, and infectious virus in CVL. Of the 3 women
with infectious virus (# 11, 25, 29), all had MIP3a and HIV
specific IgG levels that were lower than average (Table 2).
CVL from HIV(+) women have anti-HIV activity
To determine whether CVL from HIV(+) women inhibit HIV
infection of target cells, CVL were incubated with either X4- or
R5- tropic HIV-1 at MOI=1 for 1h at 37uC prior to the
measurement of HIV-1 infectivity via the TZM-bl assay. Among
individual subjects, we found a spectrum of anti-HIV activity
ranging from 2134% to 100% inhibition in CVL (Figure 2). In
Table 2, as has been reported by others [32–36], we found that
some CVL, rather than inhibiting HIV infection, had a
stimulatory effect on HIV infectivity without changing background
RLU values. Values reported as less than 0% in Table 2 indicate
stimulation and are included for completeness. The demonstration
of enhancement of viral infection beyond control HIV infection
was observed in 33 of 160 assays (20%). The pattern of inhibition
was not consistent across viral strains, except in Subject 6 who had
below average levels of endogenous microbicides. As seen in
Table 2, when compared to virus alone, anti-HIV activity was
measurable against both X4 and R5 viruses for the majority of
CVL tested. In particular, we found that CVL from some patients
had anti-HIV activity between 86–100% across all viruses
examined (Patients # 20 and 30). In other cases, we found that
anti-HIV activity varied with the virus tested (Patients # 7 and
21). As seen in Table 2, no significant differences were observed
among median values for each viral strain examined. Overall, to
the best of our knowledge, this is the first demonstration of anti-
HIV activity in CVL from North American HIV(+) women who
are healthy, and not on ARV therapy.
CVL from HIV(2) women have anti-HIV activity
To evaluate whether CVL from HIV(2) women had endog-
enous anti-HIV activity, samples from 15 healthy women were
obtained from the RI HER Repository. As shown in Table 3, we
found general inhibition of HIV infection of target cells. Similar to
HIV(+) women, CVL from HIV(2) women showed limited
enhancement of HIV infectivity beyond control infections (3 of 75
assays). Although 5/15 HIV(2) women had BV (# 3,4,5,10,15),
Figure 2. Measurement of antiviral activity in CVL from HIV(+)
women. Thirty two HIV(+) CVL were diluted 1:4 and incubated with
HIV-1 IIIB (X4-tropic) and BaL (R5-tropic) (Panel A) or NL4.3 (X4) and
YU-2.c (R5) (Panel B) at a multiplicity of infection (MOI) of 1 for 1h at
37uC prior to infecting TZM-bl cells. Data points in each graph
represents one individual patient. Media, ‘‘Control’’, and ‘‘CVL only’’
wells (Panel A) were set up as negative controls, and replica wells of
virus (IIIB, BaL, NL4.3 and YU-2.c) were set up as positive controls.
Significant differences (p values) between the mean of the control
(virus alone) and that of the cognate virus+CVL are shown in the
Figure.
doi:10.1371/journal.pone.0011366.g002
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As seen in Figures 3A and B, we found that some CVL had potent
anti-HIV activity while others had little to no activity. As with
HIV(+) healthy women, there was a wide diversity of CVL
inhibition with individual viruses.
Antiviral activity in CVL from HIV(+) and HIV(2) women
against an infectious molecularly cloned, transmitted/
founder virus
Recent studies focusing on initial HIV transmission have
identified the genetic sequences of transmitted/founder HIV-1
viruses responsible for the establishment of initial infection [27].
We evaluated the impact of CVL from HIV(+) and HIV(2)
women on infectivity of an infectious molecular clone containing
the complete nucleotide sequences of transmitted/founder virus,
CH077.c (Ochsenbauer et al. in preparation). As shown in
Figures 4A and 4B, when anti-HIV activity was evaluated between
different viruses, we found that transmitted/founder virus
(CH077.c) was inhibited by CVL from both healthy HIV(+) and
HIV(2) women as were laboratory-adapted viruses (IIIB, NL4.3,
BaL, and YU-2.c) shown in Tables 2 and 3. These findings suggest
that the CH077.c transmitted/founder virus is as susceptible to
inhibition by FRT endogenous microbicides as the other strains
tested.
CVL from HIV(+) and (2) women contain a spectrum of
antimicrobials
To define the mechanism(s) through which CVL from
HIV(+) and (2) women protect target cells from HIV infection,
we analyzed CVL specimens for key endogenous microbicide
candidates which we and others have shown in cell culture to
have antiviral activity [9–12]. Tables 2 and 3 contain a detailed
breakdown of anti-HIV activity as well as the concentrations of
4 known anti-HIV molecules measured in individual CVL
samples. Analysis of CVL from HIV(+) and (2)w o m e nf o r
SLPI, trappin-2/elafin, MIP3a, and HBD2 indicated that each
of these antivirals are present in CVL irrespective of HIV
status. Recognizing that CVL specimens from HIV(+) and (2)
women were obtained at different times and from different
repositories with slightly different protocols, it was surprising to
observe that concentrations of MIP3a and SLPI were virtually
identical (Tables 2 and 3). Moreover, the concentrations of
SLPI in CVL in our studies were comparable to that reported
previously by others [15]. Unexpectedly, we found that HBD2
levels were approximately 3-fold greater in HIV(+) women than
that seen in HIV(2) women. In contrast, HIV(2) women had
significantly (p,0.05) higher values of trappin-2/elafin than
HIV(+) women. These data suggest that HIV infection alters
the distribution of some endogenous microbicides in FRT
secretions.
Anti-gp160HIV IgA and IgG antibodies in CVL from HIV(+)
women
To determine whether the CVL of HIV(+) women had
antibodies against HIV, we assessed CVL samples for the presence
of anti-HIV gp160 specific IgG and IgA antibodies using 15 mOD
as a cut-off for detection [29]. As seen in Table 4, we found that 30
out of 32 CVL from HIV(+) women had anti-gp160HIV IgG
antibodies, while none were positive for anti-HIV IgA antibodies
(data not shown). Neither anti-HIV gp160 IgG nor IgA antibodies
were detected in CVL from HIV(2) women (Table 4).
Anti-HIV activity correlates with specific antimicrobials
and anti-HIV IgG in CVL from HIV(+) women.
Table 5 summarizes the correlation by Spearman analysis
between % inhibition of HIV infection of target cells by each
Table 3. Anti-HIV-1 activity and levels of antimicrobials in CVL from HIV(2) women.
Patient X4
%
Inhibition R5 (pg/ml)
Number IIIB NL4.3 YU-2.c BaL CH077c HBD2 Elafin MIP3a SLPI
1 14 79 41 29 73 67455 18792 53 75520
2 70 91 39 66 71 20308 15764 76 51880
3 4 78 5 8 54 18 25 4 8 7 1 8 9 2 3 9 6 0 0 0
4 66 71 93 26 87 222 4606 26 58520
5 104 97 98 31 96 1780 141 118 19190
6 34 90 44 42 78 3306 6459 124 75810
7 92 94 89 59 96 22288 2327 97 67570
8 69 85 59 22 75 906 2238 448 112000
94 6 1 0 6 6 21 50 19599 14456 90 48170
10 84 93 70 27 75 1067 3849 155 91070
11 75 77 69 18 79 4 5952 721 45080
12 101 103 105 98 74 115 214 4344 93330
13 61 92 3 59 69 27028 12821 29 51720
14 5 12 40 227 77 45 6412 71 39960
15 61 71 24 15 64 2394 8647 239 73560
MEDIAN 66 85 66 29 75 2394 5952 97 58520
INTERQUARTILE RANGE 46, 84 71, 93 40, 89 15, 59 71, 82 222, 20308 2238, 12821 53, 239 45080, 75810
doi:10.1371/journal.pone.0011366.t003
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(HBD2, trappin-2/elafin, MIP3a, SLPI) and anti-HIV gp160 IgG.
Of the 4 antimicrobials tested, we found positive correlations
between the levels of HBD2 and MIP3a as well as anti-HIV IgG
with inhibition of some HIV strains. In particular, MIP3a
correlated with anti-HIV activity against all 3 of the R5 viruses
but neither of the X4 viruses. In contrast, we found no correlation
of anti-HIV activity with SLPI and trappin-2/elafin. Similarly,
when we analyzed HBD2, MIP3a trappin-2/elafin, and SLPI vs
anti-HIV activity in CVL from HIV(2) women, we found no
evidence of a positive correlation (data not shown).
To further assess the overall contribution of each antimicrobial
and anti-HIV IgG for protection against multiple HIV viral
strains, the percent reduction in HIV infection of TZM-bl cells for
each isolate was divided into quartiles, and a score assigned to
each quartile. Then we assessed the correlation of levels of each
antimicrobial or anti-HIV IgG with the summed quartile scores
using Spearman correlation coefficients as above. As seen in
Table 5 (right column), we found significant correlations, identical
to that seen above with Spearman analysis, between the levels of
HBD2, MIP3a and anti-HIV IgG with the summed percent
reduction in HIV infection. These data are further supportive
evidence of the importance of HBD2, MIP3a and anti-HIV IgG
in protecting the FRT from multiple strains of HIV.
Discussion
The present study evaluated the presence of anti-HIV activity in
CVL from HIV(+) healthy and HIV(2) women. When analyzed
by ELISA, CVL from HIV(+) and HIV(2) women were found to
contain a spectrum of endogenous microbicides with activity
against both X4- and R5-tropic HIV.
When CXCR4 and CCR5 tropic HIV-1 were incubated with
CVL from HIV(+) women prior to addition to TZM-bl cells, anti-
Figure 4. Analysis of CH077.c (R5; transmitted/founder Virus)
activity in CVL from HIV(+) and HIV(2) women. Thirty two HIV(+)
CVL and 15 HIV(2) CVL were diluted 1:4 and incubated with the R5
transmitted/founder HIV-1 virus CH077.c at MOI 1 for 1h at 37uC prior to
infecting TZM-bl cells. Control wells incubated with CVL alone were set
up as negative controls and CH077.c wells were set up as positive
controls. Each data point in Figure 4A represents one of 32 individual
patients. In Figure 4B each data point represents one of 15 individuals.
Significant differences between control (CH077.c) and CH077.c + CVL
are indicated in Figure.
doi:10.1371/journal.pone.0011366.g004
Figure 3. Analysis of antiviral activity in CVL from HIV(2)
women. Fifteen HIV(2) CVL were diluted 1:4 and incubated with HIV-1
IIIB (X4-tropic) and BaL (R5-tropic) (Panel A) or NL4.3 (X4) and YU-2.c
(R5) (Panel B) at MOI 1 for 1h at 37uC prior to infecting TZM-bl cells.
Media only ‘‘Control’’ and virus only (IIIB, BaL, NL4.3 and YU-2.c) wells
were set up as positive controls. Each data point in graph represents
one individual patient. Data points in each graph represents one
individual patient. Significant differences between control (virus alone)
and virus+CVL are indicated in Figure.
doi:10.1371/journal.pone.0011366.g003
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some showing enhancement, depending on the viral strains used.
CVL from HIV(2) controls showed comparable anti-HIV activity.
Importantly, CVL from HIV(+) and HIV(2) women demonstrat-
ed potent antiviral activity against a molecular clone of a
transmitted/founder virus, CH077.c, that was comparable to
laboratory strains. Measurement of CVL for antimicrobials
demonstrated that HBD2 and MIP3a correlated with anti-HIV
activity as did anti-gp160 HIV IgG antibodies in CVL from
HIV(+) women.
The present studies demonstrate that CVL from HIV(+) and
HIV(2) women contain at least four microbicides with known
anti-HIV activity. We and others have examined SLPI, trappin-2/
elafin, MIP3a, and HBD2 and found that each has anti-HIV
activity [13,14,37–39]. Unexpectedly, in the present study, we
found that anti-HIV-1 activity in CVL from HIV(+) women
correlated with CVL levels of MIP3a and HBD2 but not with
SLPI or trappin-2/elafin. Interestingly, MIP3a concentrations in
HIV(+) CVL positively correlated with anti-HIV activity against
all 3 R5 HIV strains, including the transmitted/founder virus
CH077.c. In addition, anti-HIV activity in CVL from HIV(+)
women correlated significantly with anti-gp160HIV IgG antibod-
ies. This is the first study to correlate anti-HIV activity of healthy
HIV(+) CVL from North American women with the levels of anti-
HIV antibodies. While we have not established that these
antibodies possess neutralizing ability, these data clearly suggest
a role for antibodies in the immune defense against HIV
transmission. Taken together, these findings indicate that CVL
from HIV(+) and (2) women contain endogenously produced
antimicrobials that inhibit HIV infection, and in doing so may
limit both acquisition and transmission of infection.
An unexpected finding was that approximately 3/32 samples
from HIV(+) CVL examined contained virus capable of infection,
and that infectious virus was independent of plasma and genital
tract viral load. While very few studies have measured infectious
virus in CVL, others have reported similar low numbers of women
with CVL infectious virus [24]. In our study, the 3 women with
infectious virus had MIP3a and HIV-specific IgG levels that were
lower than average (Table 2 and Table 4). This finding suggests
that endogenous antimicrobials such as MIP3a and HIV-specific
IgG antibodies are too low to inactivate virus. These findings are
of particular importance because they suggest that local protection
in CVL may inactivate infectious virus to limit sexual transmission.
Others have demonstrated that low vaginal pH can inactivate
HIV [40]. That this is unlikely is suggested from studies in which
vaginal pH was measured both prior to and immediately following
ejaculation. In all cases, vaginal pH was neutralized from 5.6 to
7.2 within 6 seconds [41,42]. These findings suggest that
antivirals, such as MIP3a measured in the present study along
with other endogenous microbicides, are responsible for viral
inactivation. Further studies are essential to identify the molecules
involved in limiting the presence of infectious virus in genital tract
secretions.
It is well established that during sexual transmission, R5 strains
of HIV are selectively transmitted over X4 strains, although the
mechanisms for this are poorly understood [43–45]. An unex-
pected finding in the present study was the variation in antiviral
activity in CVL specimens between individuals and against
different viruses. This range of inhibition existed between viruses
of the same tropism (X4: IIIB and NL4.3; R5: BaL, YU-2.c and
CH077.c) and was independent of subject demographic charac-
teristics. One explanation is that variations in viral envelopes
might lead to differences in sensitivity to antivirals in CVL. For
example, SLPI and defensins have been shown to inhibit HIV
infection based on tropism [46,47]. Alternatively, since CVL
contain a spectrum of antimicrobials that vary with stage of the
menstrual cycle [15], it is likely that variations in both the quality
and quantity of antimicrobials between individuals contribute to
the diversity of antiviral activity seen in this study. The observation
that MIP3a, which we have shown to inhibit HIV infection [13],
correlated positively with anti-HIV activity against the R5, but not
the X4, HIV strains suggests a unique protective role for this
antimicrobial against HIV-1 infection. Whether viral differences,
cycle stage or heterogeneity of antimicrobials in CVL samples are
responsible remains to be determined.
Anti-HIV activity of CVL from HIV(2) women did not
correlate with the levels of any of the measured microbicides (data
not shown). One explanation for this finding is that the number of
Table 4. HIV GP160-specific IgG in CVL from HIV(+) and
HIV(2) women.
Patient #
32 HIV+
Patient ID IgG
15 HIV-
Patient ID IgG
1 B071c 583 40048 1.7
2 B083c 907 400993 1.7
3 B037c 148 400415 1.7
4 B057c 645 402382 1.5
5 B060a .1000 402757 1.2
6 B059c 13 401687 1.8
7 B013c .1000 400868 1.4
8 B006c 37 401927 1.2
9 B078c 1106 400937 0.7
10 B062a 745 401541 1
11 B011a 272 401701 1.5
12 B027c 1190 400802 12.6
13 B074c 29 400824 2.2
14 B061c 43 402428 1.6
15 B079c 529 400982 0.4
16 B015a 562
17 B086d/a 107
18 B073b 532
19 B068c .1000
20 B018c .1000
21 B012c/a 233
22 B067c 26
23 B077d/a 95
24 B051d/c 2.7
25 B085c/a 25
26 B017c 54
27 B029c 914
28 B048c 134
29 B049c 128
30 B047c 534
31 B058c/a 64
32 B075c 501
The results are in milliOD per minute but correspond directly to the amount of
binding antibody. 15 is the usual cut-off by this criteria, only two HIV infected
person lacked antibody. No antibodies were detected in HIV(2) CVL.
doi:10.1371/journal.pone.0011366.t004
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alternative explanation is that the anti-HIV activity of CVL stems
from a combination of multiple endogenous microbicides and that
the assessment of no single factor adequately captures the sum
total anti-HIV activity of any one woman’s CVL microbicides
[15,16,48]. For example, others have shown that CVL contain the
cathelicidin peptide LL37, calprotectin, alpha defensins and
lactoferrin, each of which has limited innate antimicrobial activity
but can act in synergy to inhibit HIV [9,49]. What appears not to
be involved is pH. Although low pH can selectively destabilize the
viral envelope leading to altered viral infectivity [24], all samples
tested in this study were diluted in buffered media and found to be
pH neutral (pH 7–7.2) prior to assay for anti-HIV activity.
Our studies demonstrate that CVL from a subset of women
enhanced HIV infection of target cells. This suggests that CVL
from HIV(+) women may contain factors that enhance HIV
infection. Such molecules include proinflammatory cytokines such
as IL-6, IL-8, TNFa, and IL-1a ˆ. These are often present in the
CVL in association with pre-existing infections with STI such as
bacterial vaginosis (BV), HSV-2, Trichomonas vaginalis, Neisseria
gonorrhea, and Candida albicans [50–52]. In fact, BV infection has
been frequently found to be a major correlate for enhanced HIV
replication in the FRT presumably through the enhanced
production of proinflammatory cytokines. Several of these factors
can directly enhance HIV replication by stimulating the HIV LTR
[32–34,52,53]. Another molecule found in serum and mucosal
secretions and associated with enhanced HIV replication is
myeloid related proteins MRP 8/14 [35]. Another protein, a
scavenger receptor gp340, has been shown to be expressed by
cervical and vaginal epithelium and promote trans-infection of
HIV even when the epithelium remains intact [36,54].
Some recent studies have demonstrated that the mere presence
of anti-HIV molecules in the genital tract does not necessarily
correlate with HIV neutralization activity in vivo [55,56]. This is
because some of these anti-HIV molecules such as RANTES,
LL37 and MIP3a have potent chemotactic activity and can attract
target cells to the site of infection thereby causing an enhancement
effect. Another factor that might explain the variability in HIV
neutralization ability of CVL is the amount of bioactive anti-HIV
molecules present at a given time. Bioactivity is often determined
by the presence of multiple families of proteases in the genital tract
that are responsible for specific activation and deactivation of
immune factors. The Cathepsin family of proteases regulates the
family of matrix metalloproteases, which are themselves respon-
sible for activating/deactivating innate immune factors including
the anti-HIV molecules SDF-1 and HNP1 [57–60]. Cathepsins
are also responsible for directly regulating anti-HIV innate factors
[61–63]. For example, Cathepsin D, a cysteine protease present in
vaginal secretions [49] has been shown to enhance HIV
replication [64,65]. Although the mechanisms are unclear, it is
known that Cathepsin D inhibits MIP3a [61], a known anti-HIV
factor in CVL [13]. Kallikreins (KLK) are another family of serine
proteases present in the genital mucosa that can activate/
deactivate multiple immune factors in the FRT [66] including
LL37, a potent anti-HIV molecule [67,68]. Finally, CD26/
dipeptidyl peptidase IV (DPIV) is a serine protease responsible for
the cleavage and inactivation of chemokines such as RANTES and
SDF-1, which are involved in blocking HIV entry [69,70]. A
further level of complexity arises in that, beyond their ability to
activate and inactivate FRT antimicrobials, these protease families
are regulated throughout the menstrual cycle by protease
inhibitors present in the genital secretions. Several protease
inhibitors such as SLPI and trappin-2/elafin are also known
anti-HIV molecules [12,37,71].
We examined the role of specific endogenous microbicides in the
reduction of HIV infection of target cells by CVL from HIV(+)a n d
HIV(2) women, finding that the levels of HBD2 and MIP3a
correlated significantly with inhibition of infection. HBD2 is
reported to inhibit infection through direct interaction with the
virus, as well as decreasing expression of CXCR4, the co-receptor
for X4 HIV-1 viruses (but not CCR5) in peripheral blood
mononuclear cells and T lymphocytic cells as shown by confocal
microscopy and flow cytometry [46]. Sun et. al. did not find a
decrease in co-receptor expression with HBD2 treatment, and
Tables 5. Correlation of levels of antimicrobials and anti-HIV IgG in CVL with anti-HIV activity against 5 different viruses.
% Reduction in Target Cell Infection with Indicated Strain
HIV+ (N=32) IIIB (X4) NL4.3 (X4) BaL (R5) YU-2.c (R5) CH077.c (R5)
Percent reduction against all
viruses, summed quartiles
HBD2
Spearman’s r 0.391 0.28 0.53 0.288 0.283 0.395
P value 0.027 0.121 0.002 0.109 0.116 0.025
Elafin
Spearman’s r 20.053 20.178 20.009 20.095 20.198 20.091
P value 0.772 0.331 0.961 0.605 0.277 0.619
MIP3a
Spearman’s r 0.278 0.271 0.425 0.382 0.4 0.397
P value 0.124 0.134 0.015 0.031 0.023 0.025
SLPI
Spearman’s r 0.033 20.053 0.184 0.136 20.017 0.079
P value 0.859 0.775 0.315 0.46 0.925 0.668
Anti-HIV IgG
Spearman’s r 0.484 0.117 0.595 0.517 0.283 0.502
P value 0.005 0.526 0.001 0.002 0.117 0.003
doi:10.1371/journal.pone.0011366.t005
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[72]. We found that HBD2 and SLPI are present in CVL at
concentrations comparable to previous reports [15,73,74]. Notably,
CVL from HIV(+) women had significantly higher HBD2 than
HIV(2) women, suggesting that HIV infection upregulates the
production of this potentially protective endogenous microbicide.
One explanation for the variability seen in anti-HIV activity
(innate and specific IgG antibodies) in the present study is that it
was not possible to collect CVL from HIV(2) and HIV(+) women
according to stage of the menstrual cycle. As discussed elsewhere
[48], innate and adaptive immunity throughout the female
reproductive tract are under hormonal control. For example, we
found that midcycle suppression of the humoral immunity by
estradiol, which confirms the findings of other laboratories [75,76],
extends to endogenous antimicrobials in CVL [15]. Analysis of the
concentrations of cytokines, chemokines and antimicrobials in
CVL indicated that SLPI, HBD2, HNP1-3 and lactoferrin
dropped significantly at midcycle (day 13) and remained depressed
for 7–10 days prior to returning to proliferative phase levels just
prior to menstruation. Therefore, owing to hormonal changes
during the menstrual cycle, antimicrobials and antibodies may not
be present at concentrations sufficient to exert anti-HIV effects.
Thus, without compensating mechanisms, innate immune protec-
tion is suppressed transiently at midcycle to optimize the chances
for successful fertilization, implantation and pregnancy. What is
likely is that antiviral activity in CVL is the net and possibly
synergistic result of 12–20 antimicrobials present at varying
concentrations over the course of the menstrual cycle. Studies to
assess the spectrum of antimicrobials in CVL and the ways in
which each is altered during the menstrual cycle are essential for a
complete understanding of the role of the innate immune system in
protection and control of sexual transmission of HIV.
Other studies have demonstrated the presence of anti-HIV
antibodies in CVL from HIV(+) women [1,77–79], but to the best
of our knowledge, ours is the first to correlate the levels of these
antibodies with anti-HIV activity in CVL from healthy North
American HIV(+) women not on any ARVs. These results should
prompt an assessment of whether these antibodies exhibit
neutralizing activity against HIV, or if the correlation with
protection of target cells arises from other mechanisms. Binding
but non-neutralizing IgG in the CVL of HIV(+) women has been
shown to be protective by lowering viral loads and presenting
better clinical outcomes [80]. Such antibodies are believed to
protect by inducing ADCC (antibody dependent cellular cytotox-
icity) and ADCVI (Antibody dependent cell mediated viral
inhibition) [81]. In fact, the recent vaccine trial in Thailand shows
preliminary data indicative of protective effects from binding but
non-neutralizing antibodies [82]. We also found, similar to other
studies [78,79,83], that CVL from HIV(+) women lacked anti-
HIV specific IgA antibodies, suggesting that IgA in the FRT might
not play a substantive role in protection from HIV transmission.
In summary, this study demonstrates that CVL from healthy
HIV(+) and HIV(2) women have intrinsic anti-HIV activity and
that this activity is most likely mediated through a spectrum of
endogenously produced antimicrobials which are capable of
inhibiting X4 and R5 viruses. Whereas a spectrum of factors
capable of mediating antimicrobial protection are present in CVL,
the levels of HBD2, MIP3a and HIV specific IgG antibodies
correlated with protection of target cells from infection with HIV.
These findings highlight the need for additional studies to more
fully understand the influences of the innate immune system and
its regulation by sex hormones during the menstrual cycle,
pregnancy and following menopause in immune protection
throughout the reproductive tract. Moreover, it suggests that a
clear understanding of innate protection in the female reproduc-
tive tract may lead to new candidate microbicides and approaches
for microbicide-mediated immune protection.
Acknowledgments
The authors thank Richard Rossoll, M.S., Dartmouth Medical School,
Deena Ratner, B.S., University of Pittsburgh, Irma Rodriguez, Brown
University, and Jessica Ingersoll, M.S., Emory University, for excellent
technical assistance in the preparation of samples, cells and virus stocks.
The authors also thank Dr Phalguni Gupta, University of Pittsburgh, for
generous sharing of reagents and information.
Author Contributions
Conceived and designed the experiments: MG JVF SCU KHM CRW.
Performed the experiments: MG ZS PFW. Analyzed the data: MG JVF ZS
TL ZW PFW CO CRW. Contributed reagents/materials/analysis tools:
SCU KHM PFW JCK CO. Wrote the paper: MG JVF TL PFW CO
CRW.
References
1. Mestecky J (2007) Humoral immune responses to the human immunodeficiency
virus type-1 (HIV-1) in the genital tract compared to other mucosal sites.
J Reprod Immunol 73: 86–97.
2. CDC (2008) HIV/AIDS Among Women. http://wwwcdcgov/hiv/topics/
women/resources/factsheets/pdf/womenpdf.
3. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, et al.
(2001) Probability of HIV-1 transmission per coital act in monogamous,
heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357: 1149–53.
4. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, et al. (2005) Rates
of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai,
Uganda. J Infect Dis 191: 1403–9.
5. Fahey JV, Wright JA, Shen L, Smith JM, Ghosh M, et al. (2008) Estradiol
selectively regulates innate immune function by polarized human uterine
epithelial cells in culture. Mucosal Immunol 1: 317–25.
6. Ghosh M, Schaefer TM, Fahey JV, Wright JA, Wira CR (2008) Antiviral
responses of human Fallopian tube epithelial cells to toll-like receptor 3 agonist
poly(I:C). Fertil Steril 89: 1497–506.
7. King AE, Fleming DC, Critchley HO, Kelly RW (2003) Differential expression
of the natural antimicrobials, beta-defensins 3 and 4, in human endometrium.
J Reprod Immunol 59: 1–16.
8. Schaefer TM, Fahey JV, Wright JA, Wira CR (2005) Innate immunity in the
human female reproductive tract: antiviral response of uterine epithelial cells to
the TLR3 agonist poly(I:C). J Immunol 174: 992–1002.
9. Cole AM, Cole AL (2008) Antimicrobial polypeptides are key anti-HIV-1 effector
molecules of cervicovaginal host defense. Am J Reprod Immunol 59: 27–34.
10. Iqbal SM, Kaul R (2008) Mucosal innate immunity as a determinant of HIV
susceptibility. Am J Reprod Immunol 59: 44–54.
11. Cole AM (2006) Innate host defense of human vaginal and cervical mucosae.
Curr Top Microbiol Immunol 306: 199–230.
12. MoreauT,BarangerK,DadeS,Dallet-ChoisyS,GuyotN,etal.(2008)Multifaceted
roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine
protease inhibitors of the chelonianin family. Biochimie 90: 284–95.
13. Ghosh M, Shen Z, Schaefer TM, Fahey JV, Gupta P, et al. (2009) CCL20/
MIP3alpha is a novel anti-HIV-1 molecule of the human female reproductive
tract. Am J Reprod Immunol 62: 60–71.
14. Garzino-Demo A (2007) Chemokines and defensins as HIV suppressive factors:
an evolving story. Curr Pharm Des 13: 163–72.
15. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, et al. (2007) PRO
2000 elicits a decline in genital tract immune mediators without compromising
intrinsic antimicrobial activity. Aids 21: 467–76.
16. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM (2005) Cationic
polypeptides are required for anti-HIV-1 activity of human vaginal fluid.
J Immunol 175: 7560–7.
17. Vogt MW, Witt DJ, Craven DE, Byington R, Crawford DF, et al. (1986)
Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS.
Lancet 1: 525–7.
18. Henin Y, Mandelbrot L, Henrion R, Pradinaud R, Coulaud JP, et al. (1993)
Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant
HIV-infected women. J Acquir Immune Defic Syndr 6: 72–5.
19. Kreiss J, Willerford DM, Hensel M, Emonyi W, Plummer F, et al. (1994)
Association between cervical inflammation and cervical shedding of human
immunodeficiency virus DNA. J Infect Dis 170: 1597–601.
20. Moss GB, Clemetson D, D’Costa L, Plummer FA, Ndinya-Achola JO, et al.
(1991) Association of cervical ectopy with heterosexual transmission of human
Secreted Anti-HIV Activity
PLoS ONE | www.plosone.org 10 June 2010 | Volume 5 | Issue 6 | e11366immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect
Dis 164: 588–91.
21. Reichelderfer PS, Coombs RW, Wright DJ, Cohn J, Burns DN, et al. (2000)
Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital
tract. WHS 001 Study Team. Aids 14: 2101–7.
22. Villanueva JM, Ellerbrock TV, Lennox JL, Bush TJ, Wright TC, et al. (2002)
The menstrual cycle does not affect human immunodeficiency virus type 1 levels
in vaginal secretions. J Infect Dis 185: 170–7.
23. Benki S, Mostad SB, Richardson BA, Mandaliya K, Kreiss JK, et al. (2008)
Increased levels of HIV-1-infected cells in endocervical secretions after the
luteinizing hormone surge. J Acquir Immune Defic Syndr 47: 529–34.
24. Cummins JE, Jr., Villanueva JM, Evans-Strickfaden T, Sesay SM, Abner SR,
et al. (2003) Detection of infectious human immunodeficiency virus type 1 in
female genital secretions by a short-term culture method. J Clin Microbiol 41:
4081–8.
25. Kovacs A, Chan LS, Chen ZC, Meyer WA, 3rd, Muderspach L, et al. (1999)
HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-
1. J Acquir Immune Defic Syndr 22: 124–31.
26. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of
resistant human immunodeficiency virus type 1 in patients receiving fusion
inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–905.
27. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008)
Identification and characterization of transmitted and early founder virus
envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552–7.
28. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009)
Genetic identity, biological phenotype, and evolutionary pathways of transmit-
ted/founder viruses in acute and early HIV-1 infection. J Exp Med 206:
1273–89.
29. Wright PF, Kozlowski PA, Rybczyk GK, Goepfert P, Staats HF, et al. (2002)
Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res
Hum Retroviruses 18: 1291–300.
30. Cu-Uvin S, Snyder B, Harwell JI, Hogan J, Chibwesha C, et al. (2006)
Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA
levels during 36 months. J Acquir Immune Defic Syndr 42: 584–7.
31. Spear GT, St John E, Zariffard MR (2007) Bacterial vaginosis and human
immunodeficiency virus infection. AIDS Res Ther 4: 25.
32. Lane BR, Lore K, Bock PJ, Andersson J, Coffey MJ, et al. (2001) Interleukin-8
stimulates human immunodeficiency virus type 1 replication and is a potential
new target for antiretroviral therapy. J Virol 75: 8195–202.
33. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, et al. (1990) Interleukin 6
induces human immunodeficiency virus expression in infected monocytic cells
alone and in synergy with tumor necrosis factor alpha by transcriptional and
post-transcriptional mechanisms. J Exp Med 172: 151–8.
34. Spear GT, Zariffard MR, Chen HY, Anzinger JJ, Anastos K, et al. (2008)
Positive association between HIV RNA and IL-6 in the genital tract of Rwandan
women. AIDS Res Hum Retroviruses 24: 973–6.
35. Hashemi FB, Mollenhauer J, Madsen LD, Sha BE, Nacken W, et al. (2001)
Myeloid-related protein (MRP)-8 from cervico-vaginal secretions activates HIV
replication. Aids 15: 441–9.
36. Stoddard E, Cannon G, Ni H, Kariko K, Capodici J, et al. (2007) gp340
expressed on human genital epithelia binds HIV-1 envelope protein and
facilitates viral transmission. J Immunol 179: 3126–32.
37. Ghosh M, Shen Z, Fahey JV, Cu-Uvin S, Mayer K, et al. (2009) Trappin-2/
Elafin: a novel innate anti-HIV-1 molecule of the human female reproductive
tract. Immunology, In press.
38. McNeely T, Shugars D, Rosendahl M, Tucker C, Eisenberg S, et al. (1997)
Inhibition of human immunodeficiency virus type 1 infectivity by secretory
leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90:
1141–9.
39. Bingle CD, Vyakarnam A (2008) Novel innate immune functions of the whey
acidic protein family. Trends Immunol 29: 444–53.
40. Hillier S (1998) The vaginal microbial ecosystem and resistance to HIV. AIDS
Res Hum Retroviruses Suppl 1: S17–21.
41. Fox CA, Meldrum SJ, Watson BW (1973) Continuous Measurement by radio-
telemetry of vaginal pH during human coitus. J Reprod Fert 33: 69–75.
42. Tevi-Benissan C, Belec L, Levy M, Schneider-Fauveau V, Si Mohamed A, et al.
(1997) In vivo semen-associated pH neutralization of cervicovaginal secretions.
Clin Diagn Lab Immunol 4: 367–74.
43. Margolis L, Shattock R (2006) Selective transmission of CCR5-utilizing HIV-1:
the ‘gatekeeper’ problem resolved? Nat Rev Microbiol 4: 312–7.
44. Berlier W, Bourlet T, Lawrence P, Hamzeh H, Lambert C, et al. (2005)
Selective sequestration of X4 isolates by human genital epithelial cells:
Implication for virus tropism selection process during sexual transmission of
HIV. J Med Virol 77: 465–74.
45. Saidi H, Magri G, Nasreddine N, Requena M, Belec L (2007) R5- and X4-HIV-
1 use differentially the endometrial epithelial cells HEC-1A to ensure their own
spread: implication for mechanisms of sexual transmission. Virology 358: 55–68.
46. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, et al.
(2003) Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids
17: F39–48.
47. Skott P, Lucht E, Ehnlund M, Bjorling E (2002) Inhibitory function of secretory
leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and
varies with virus tropism. Oral Dis 8: 160–7.
48. Wira CR, Fahey JV (2008) A new strategy to understand how HIV infects
women: identification of a window of vulnerability during the menstrual cycle.
Aids 22: 1909–17.
49. Cummins JE, Christensen L, Lennox JL, Bush TJ, Wu Z, et al. (2006) Mucosal
innate immune factors in the female genital tract are associated with vaginal
HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses
22: 788–95.
50. Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, et al. (2007)
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and
RANTES and the effects of coexisting vaginoses in human immunodeficiency
virus (HIV)-seronegative women with a high risk of heterosexual acquisition of
HIV infection. Clin Vaccine Immunol 14: 1102–7.
51. Sha BE, D’Amico RD, Landay AL, Spear GT, Massad LS, et al. (1997)
Evaluation of immunologic markers in cervicovaginal fluid of HIV-infected and
uninfected women: implications for the immunologic response to HIV in the
female genital tract. J Acquir Immune Defic Syndr Hum Retrovirol 16: 161–8.
52. Spear GT, Zariffard MR, Cohen MH, Sha BE (2008) Vaginal IL-8 levels are
positively associated with Candida albicans and inversely with lactobacilli in
HIV-infected women. J Reprod Immunol 78: 76–9.
53. Ryckman C, Robichaud GA, Roy J, Cantin R, Tremblay MJ, et al. (2002) HIV-
1 transcription and virus production are both accentuated by the proinflamma-
tory myeloid-related proteins in human CD4+ T lymphocytes. J Immunol 169:
3307–13.
54. Cannon G, Yi Y, Ni H, Stoddard E, Scales DA, et al. (2008) HIV envelope
binding by macrophage-expressed gp340 promotes HIV-1 infection. J Immunol
181: 2065–70.
55. Kaul R, Pettengell C, Sheth PM, Sunderji S, Biringer A, et al. (2008) The genital
tract immune milieu: an important determinant of HIV susceptibility and
secondary transmission. J Reprod Immunol 77: 32–40.
56. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, et al. (2009) Levels of innate
immune factors in genital fluids: association of alpha defensins and LL-37 with
genital infections and increased HIV acquisition. Aids 23: 309–17.
57. Jokimaa V, Oksjoki S, Kujari H, Vuorio E, Anttila L (2001) Expression patterns
of cathepsins B, H, K, L and S in the human endometrium. Mol Hum Reprod 7:
73–8.
58. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, et al.
(2000) Inflammation dampened by gelatinase A cleavage of monocyte
chemoattractant protein-3. Science (New York, NY 289: 1202–6.
59. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, et al. (1999)
Regulation of intestinal alpha-defensin activation by the metalloproteinase
matrilysin in innate host defense. Science (New York, NY 286: 113–7.
60. Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, et al. (2003) HIV-
induced metalloproteinase processing of the chemokine stromal cell derived
factor-1 causes neurodegeneration. Nat Neurosci 6: 1064–71.
61. Hasan L, Mazzucchelli L, Liebi M, Lis M, Hunger RE, et al. (2006) Function of
liver activation-regulated chemokine/CC chemokine ligand 20 is differently
affected by cathepsin B and cathepsin D processing. J Immunol 176: 6512–22.
62. Taggart CC, Greene CM, Smith SG, Levine RL, McCray PB, Jr., et al. (2003)
Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins.
J Immunol 171: 931–7.
63. Lim JK, Lu W, Hartley O, DeVico AL (2006) N-terminal proteolytic processing
by cathepsin G converts RANTES/CCL5 and related analogs into a truncated
4–68 variant. J Leukoc Biol 80: 1395–404.
64. El Messaoudi K, Thiry L, Van Tieghem N, Liesnard C, Englert Y, et al. (1999)
HIV-1 infectivity and host range modification by cathepsin D present in human
vaginal secretions. Aids 13: 333–9.
65. El Messaoudi K, Thiry LF, Liesnard C, Van Tieghem N, Bollen A, et al. (2000)
A human milk factor susceptible to cathepsin D inhibitors enhances human
immunodeficiency virus type 1 infectivity and allows virus entry into a mammary
epithelial cell line. J Virol 74: 1004–7.
66. Shaw JL, Petraki C, Watson C, Bocking A, Diamandis EP (2008) Role of tissue
kallikrein-related peptidases in cervical mucus remodeling and host defense. Biol
Chem 389: 1513–22.
67. Steinstraesser L, Tippler B, Mertens J, Lamme E, Homann HH, et al. (2005)
Inhibition of early steps in the lentiviral replication cycle by cathelicidin host
defense peptides. Retrovirology 2: 2.
68. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, et al. (2006)
Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelici-
dins in skin. Faseb J 20: 2068–80.
69. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, et al. (1997)
Regulation of the receptor specificity and function of the chemokine RANTES
(regulated on activation, normal T cell expressed and secreted) by dipeptidyl
peptidase IV (CD26)-mediated cleavage. J Exp Med 186: 1865–72.
70. Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, et al. (1998) Anti-HIV-1
and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-
1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-
mediated cleavage. Proc Natl Acad Sci U S A 95: 6331–6.
71. Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, et al. (2009) Elevated
elafin/trappin-2 in the female genital tract is associated with protection against
HIV acquisition. Aids 23: 1669–77.
72. Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, et al.
(2005) Human beta-defensins suppress human immunodeficiency virus infection:
potential role in mucosal protection. J Virol 79: 14318–29.
Secreted Anti-HIV Activity
PLoS ONE | www.plosone.org 11 June 2010 | Volume 5 | Issue 6 | e1136673. Cummins JE, Jr., Denniston M, Mayer KH, Pickard R, Novak RM, et al. (2007)
Mucosal innate immune factors in secretions from high-risk individuals
immunized with a bivalent gp120 vaccine. AIDS Res Hum Retroviruses 23:
748–54.
74. Fan SR, Liu XP, Liao QP (2008) Human defensins and cytokines in vaginal
lavage fluid of women with bacterial vaginosis. Int J Gynaecol Obstet 103: 50–4.
75. Schumacher G (1973) Soluble proteins in cervical mucus. In: The biology of the
cervix The University of Chicago Press. pp 201–33.
76. Nardelli-Haefliger DJ, Wirthner D, Schiller J, Lowy D, Hildesheim A, et al.
(2003) Specific Antibody Levels at the Cervix During the Menstrual Cycle of
Women Vaccinated With Human Papillomavirus 16 Virus–Like Particles. J Nat
Cancer Inst 95: 1128–37.
77. Alexander R, Mestecky J (2007) Neutralizing antibodies in mucosal secretions:
IgG or IgA? Curr HIV Res 5: 588–93.
78. Fiore JR, Laddago V, Lepera A, La Grasta L, Di Stefano M, et al. (2000)
Limited secretory-IgA response in cervicovaginal secretions from HIV-1
infected, but not high risk seronegative women: lack of correlation to genital
viral shedding. New Microbiol 23: 85–92.
79. Kang G, Samuel R, Vijayakumar TS, Selvi S, Sridharan G, et al. (2005)
Community prevalence of antibodies to human immunodeficiency virus in rural
and urban Vellore, Tamil Nadu. Natl Med J India 18: 15–7.
80. Nag P, Kim J, Sapiega V, Landay AL, Bremer JW, et al. (2004) Women with
cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital
HIV-1 RNA loads. J Infect Dis 190: 1970–8.
81. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, et al. (2009) Contribution
of nonneutralizing vaccine-elicited antibody activities to improved protective
efficacy in rhesus macaques immunized with Tat/Env compared with
multigenic vaccines. J Immunol 182: 3718–27.
82. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al.
(2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in
Thailand. N Engl J Med 361: 2209–20.
83. Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, et al. (2004)
Paucity of antigen-specific IgA responses in sera and external secretions of HIV-
type 1-infected individuals. AIDS Res Hum Retroviruses 20: 972–88.
Secreted Anti-HIV Activity
PLoS ONE | www.plosone.org 12 June 2010 | Volume 5 | Issue 6 | e11366